In three nested casecontrol studies from England and Wales, involving 440,089 patients with T2DM and without ASCVD treated with non-insulin glucose-lowering medication, combined SGLT2i and GLP-1RA therapy used for primary prevention was associated with 30% lower odds of MACE (defined as myocardial infarction/acute coronary syndrome, stroke/transient ischemic attack, and/or cardiovascular death) compared with other combination regimens (OR, 0.70
Rather than managing four separate peptides, KLOWs pre-mixed formulation ensures consistent ratios, simplifies dosing, and speeds up assay setupso you can focus on results, not logistics
There are several theories of anti-inflammatory components in the NRF-2 pathway that, in a selective manner, intervene in the inflammatory process at pulmonary, renal, urinary, and hepatic levels [19]
Remember, this information is meant to educate you, so always chat with your Patient Care Coordinator if you're interested in trying these medications